SCHEMBL1684597

SCHEMBL1684597

CN(C)c1ccc(Nc2nccc(-c3cnc4ncccn34)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.63
CDK2 P24941 9/20 0.59
CDK4 P11802 3/20 0.49
CDK1 P06493 2/20 0.49
CCNE1 P24864 2/20 0.49
AURKA O14965 1/20 0.49
CDK7 P50613 1/20 0.49
CDK9 P50750 1/20 0.49
AURKB Q96GD4 1/20 0.49
IGF1R P08069 2/20 0.48
PKM P14618 5/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684800 0.88 DYRK1A (0.60) DYRK1ACDK2CDK4CDK1IGF1R
SCHEMBL1684759 0.88 DYRK1A (0.54) DYRK1ACDK2CDK4CDK1IGF1R
SCHEMBL6246038 0.86 DYRK1A (0.57) DYRK1ACDK2CDK4CDK1CCNE1
SCHEMBL1684522 0.85 PKM (0.65) DYRK1ACDK2IGF1RPKMMAPT
SCHEMBL1684858 0.85 DYRK1A (0.54) DYRK1ACDK2CDK4CDK1IGF1R
SCHEMBL1684809 0.84 CDK2 (0.67) DYRK1ACDK2CDK4CDK1CCNE1
SCHEMBL1684811 0.84 CDK2 (0.59) DYRK1ACDK2AURKBIGF1RPKM
SCHEMBL1684750 0.83 SYK (0.55) DYRK1ACDK2CDK4CDK1IGF1R
SCHEMBL1684718 0.83 CDK2 (0.52) DYRK1ACDK2IGF1RPKMIKBKB
SCHEMBL1684609 0.81 MAPT (0.67) CDK2CDK4CDK1CCNE1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A DYRK1A 4394/4885CDK2 1442/4885CDK4 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.